natgillin/translations-raw huggingface dataset:
In a single-dose study of efavirenz, half-life was doubled in the single patient with severe hepatic impairment (Child-Pugh-Turcotte Class C), indicating a potential for a much greater degree of accumulation.
U ispitivanju efavirenza s jednokratkom dozom, poluvrijeme je udvostručeno u jedinog pacijenta s teškim oštećenjem funkcije jetre (stadij C Child-Pugh-Turcotte), što ukazuje na potencijal puno višeg stupnja akumulacije.
In a single-dose study, exposure to silodosin (unbound) in subjects with mild (n=8) and moderate renal impairment (n=8) resulted, on average, in an increase of Cmax (1.6-fold) and AUC (1.7-fold) relative to subjects with normal renal function (n=8).
U ispitivanju jednokratne doze, izloženost silodozinu (nevezanom) u ispitanika s blagim (n=8) i umjerenim oštećenjem funkcije bubrega (n=8) u prosjeku je rezultiralo povećanjem Cmax (1,6 puta) i AUC (1,7 puta) u usporedbi s onima u ispitanika s normalnom funkcijom bubrega (n=8).
In a single-dose study, half life was doubled in the single patient with severe hepatic impairment (Child Pugh Class C), indicating a potential for a much greater degree of accumulation.
U ispitivanju s primjenom jednokratne doze lijeka u jedinog bolesnika s teškim oštećenjem jetre (Child- Pugh stadij C) poluvijek efavirenza bio je dvostruko dulji, što upućuje na mogućnost puno veće akumulacije lijeka.
In a single-dose study, retigabine was eliminated more slowly by healthy elderly volunteers (66 to 82 years of age) relative to healthy young adult volunteers, resulting in a higher AUC (approximately 40 to 50%) and longer terminal half-life (30%) (see section 4.2).
U ispitivanju jednokratne doze retigabin se u starijih zdravih dobrovoljaca (od 66 do 82 godine), u usporedbi sa zdravim mlađim dobrovoljcima, izlučivao sporije što je rezultiralo višim AUC-om (oko 40 do 50%) i dužim terminalnim poluvijekom (30%) (vidjeti dio 4.2).
In a single-dose study, retigabine was eliminated more slowly by healthy elderly volunteers (66 to 82 years of age) relative to healthy young adult volunteers, resulting in a higher AUC (approximately 40 to 50%) and longer terminal half-life (30%) (see section 4.2).
U ispitivanju jednokratne doze retigabin se u starijih zdravih dobrovoljaca (od 66 do 82 godine), u usporedbi sa zdravim mlađim dobrovoljcima, izlučivao sporije što je rezultiralo višim AUC-om (oko 40 do 50%) i dužim terminalnim poluživotom (30%) (vidjeti dio 4.2).
In a six-month multicentre double-blind randomised trial, 0.1% tacrolimus ointment was administered twice-a-day to adults with moderate to severe atopic dermatitis and compared to a topical corticosteroid based regimen (0.1% hydrocortisone butyrate on trunk and extremities, 1% hydrocortisone acetate on face and neck).
U šestomjesečnom, multicentričnom, dvostruko slijepom, randomiziranom ispitivanju, mast s 0,1% takrolimusa primjenjivana je dvaput na dan odraslima s umjerenim do teškim atopijskim dermatitisom i uspoređena s režimom na temelju topikalnih koritkosteroida (0,1% hidrokortizon butiratom za trup i ekstremitete, 1% hidrokortizon acetatom za lice i vrat).
In a small number of cases, these may be signs of a second degree burn and need urgent attention. o Frequency not known: frequency cannot be estimated from the available data
U malom broju slučajeva ovo mogu biti znaci opekline drugog stupnja i zahtijevaju hitnu pozornost. o nepoznata učestalost: učestalost se ne može procijeniti iz dostupnih podataka
In a small number of patients (< 10 %), doses up to 1.0 MIU (10 μg)/kg/day were required to achieve reversal of neutropenia.
U malog broja bolesnika (< 10 %) za ispravljanje neutropenije bile su nužne doze do 1,0 MIU (10 mikrograma)/kg/dan.
In a small number of patients (< 10%), doses up to 1.0 MU (10 micrograms)/kg/day were required to achieve reversal of neutropenia.
U malog broja bolesnika (< 10%) su za korekciju neutropenije bile nužne doze do 1,0 MU (10 mikrograma)/kg/dan.
In a small number of patients (< 10%), doses up to 1.0 MU/kg/day (10 micrograms/kg/day) were required to achieve reversal of neutropenia.
Malom broju bolesnika (<10%), bile su potrebne doze do 1,0 MU/kg/dan (10 mikrograma/kg/dan) kako bi se postigao obrat neutropenije.
In a small number of patients (< 10%), doses up to 1.0 MU/kg/day (10 μg/kg/day) were required to achieve reversal of neutropenia.
U malog broja bolesnika (< 10 %) bile su potrebne doze do 1,0 MU/kg na dan (10 μg/kg na dan) da bi se postigao oporavak neutropenije.
In a small number of patients (n = 23) with clinical chemistry data suggestive of mild to moderate liver function impairment (ALT, AST ≥ 1.5 times the ULN associated with alkaline phosphatase ≥ 2.5 times the ULN), total clearance was lowered by 27% on average (see section 4.2).
U malog broja bolesnika (n=23), gdje su kliničko-kemijski podaci pokazivali lagano ili srednje oštećenje jetrene funkcije (ALT, AST ≥ 1,5 puta od GGN te alkalna fosfataza ≥ 2,5 puta od GGN), ukupni klirens bio je smanjen u prosjeku 27% (vidjeti dio 4.2).
In a small number of patients (n = 23) with clinical chemistry data suggestive of mild to moderate liver function impairment (ALT, AST ≥1.5 times the ULN associated with alkaline phosphatase ≥ 2.5 times the ULN), total clearance was lowered by 27% on average (see section 4.2).
U malog broja bolesnika (n=23), gdje su klinički biokemijski podaci pokazivali lagano ili srednje oštećenje jetrene funkcije (ALT, AST ≥ 1,5 puta od GGN te alkalna fosfataza ≥ 2,5 puta od GGN), ukupni klirens bio je smanjen u prosjeku 27% (vidjeti dio 4.2).
In a small number of patients (n=23) with clinical chemistry data suggestive of mild to moderate liver function impairment (ALT, AST ≥1.5 times the ULN associated with alkaline phosphatase ≥2.5 times the ULN), total clearance was lowered by 27% on average (see section 4.2).
U malog broja bolesnika (n=23), gdje su klinički biokemijski podaci pokazivali lagano ili srednje oštećenje jetrene funkcije (ALT, AST ≥ 1,5 puta od GGN te alkalna fosfataza ≥ 2,5 puta od GGN), ukupni klirens bio je smanjen u prosjeku 27% (vidjeti dio 4.2).
In a small parallel group design study in Japanese patients with IPF (13 patients received nintedanib on top of chronic treatment with standard doses of pirfenidone; 11 patients received nintedanib alone), exposure to nintedanib decreased to 68.3% based on AUC and to 59.2% based on Cmax upon co- administration with pirfenidone pirfenidone compared to administration of nintedanib alone.
U malom ispitivanju dizajniranom na paralelnim skupinama u japanskih bolesnika s IPF-om (13 bolesnika je primalo nintedanib uz kronično liječenje standardnim dozama pirfenidona; 11 bolesnika je primalo samo nintedanib), izloženost nintedanibu se smanjivala do 68,3% na temelju AUC-a te do 59,2% na temelju Cmax nakon istodobne primjene s pirfenidonom u usporedbi s primjenom samo nintedaniba.
In a small prospective study in women (n = 64) who became inadvertently pregnant while taking leflunomide for no more than three weeks after conception and followed by a drug elimination procedure, no significant differences (p = 0.13) were observed in the overall rateof major structural defects (5.4 %) compared to either of the comparison groups (4.2 % in the disease matched group [n = 108] and 4.2 % in healthy pregnant women [n = 78]).
U manjem prospektivnom ispitivanju u žena (n = 64) koje su neplanirano ostale u drugom stanju dok su uzimale leflunomid u trajanju od ne više od tri tjedna nakon začeća i nakon postupka eliminacije lijeka nisu zabilježene značajne razlike (p = 0,13) u cjelokupnoj stopi većih strukturnih oštećenja (5,4 %) u odnosu na bilo koju od komparativnih skupina (4,2 % u bolesnih žena [n = 108] i 4,2 % u zdravih trudnica [n = 78]).
In a smoking cessation clinical trial, neuropsychiatric adverse events were reported more frequently in patients with a history of psychiatric disorders compared to those without a history of psychiatric disorders, regardless of treatment (see section 5.1).
U kliničkim ispitivanjima odvikavanja od pušenja, neuropsihijatrijski štetni događaji zabilježeni su češće kod bolesnika s psihijatrijskim poremećajima u anamnezi u usporedbi s onima bez psihijatrijskih poremećaja u anamnezi, neovisno o liječenju (vidjeti dio 5.1).
In a specific interaction study, where oral sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.
U specifičnom ispitivanju interakcije, u kojemu se sildenafil (100 mg) primjenjivao peroralno zajedno s amlodipinom u hipertenzivnih bolesnika, zabilježeno je dodatno sniženje sistoličkog krvnog tlaka u ležećem položaju od 8 mmHg.
In a specific sexual dysfunction comparative trial with remitted depressed patients, there was a numerical trend (not statistically significant) towards less sexual emergent dysfunction than venlafaxine for Sex Effects Scale (SEXFX) drive arousal or orgasm scores on Thymanax.
U posebnom komparativnom ispitivanju seksualne disfunkcije u bolesnika s remisijom depresije, postojao je numerički trend (statistički neznatan) prema manjem broju novonastalih seksualnih disfunkcija s lijekom Thymanax u odnosu na venlafaksin na ljestvici učinaka na seksualnost (SEXFX, Sex Effects Scale) koja se odnosila na libido, uzbuđenje ili orgazam.
In a specific sexual dysfunction comparative trial with remitted depressed patients, there was a numerical trend (not statistically significant) towards less sexual emergent dysfunction than venlafaxine for Sex Effects Scale (SEXFX) drive arousal or orgasm scores on Valdoxan.
U posebnom komparativnom ispitivanju seksualne disfunkcije u bolesnika s remisijom depresije, postojao je numerički trend (statistički neznatan) prema manjem broju novonastalih seksualnih disfunkcija s lijekom Valdoxan u odnosu na venlafaksin na ljestvici učinaka na seksualnost (SEXFX, Sex Effects Scale) koja se odnosila na libido, uzbuđenje ili orgazam.
In a specific study involving cirrhotic patients with chronic mild (Child-Pugh type A) or moderate (Child-Pugh type B) liver impairment, exposure to agomelatine 25 mg was substantially increased (70- times and 140-times, respectively), compared to matched volunteers (age, weight and smoking habit) with no liver failure (see section 4.2, 4.3 and 4.4).
U posebnoj studiji koja je obuhvaćala bolesnike sa cirozom jetre, s kroničnim blagim (Child-Pugh A stadij bolesti) ili umjerenim (Child-Pugh B stadij) oštećenjem jetre, izloženost agomelatinu od 25 mg bila je značajno povećana (70 odnosno 140 puta), u usporedbi s odgovarajućim dobrovoljcima (s obzirom na dob, tjelesnu težinu i pušenje) koji nisu imali zatajenje jetre (vidjeti dijelove 4.2, 4.3 i 4.4).
In a studies of denosumab (60 mg, n = 55 and 120 mg, n = 32) in patients without advanced cancer but with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of denosumab; thus dose adjustment for renal impairment is not required.
U ispitivanjima s denosumabom (60 mg, n = 55 i 120 mg, n = 32) u bolesnika bez uznapredovalog raka, ali s različitim stupnjevima bubrežne funkcije, uključujući bolesnike na dijalizi, stupanj oštećenja bubrega nije imao nikakvog učinka na farmakokinetiku denosumaba, te stoga prilagodba doze kod oštećenja bubrega nije potrebna.
In a studies of MabThera given on its own (203 patients), 48% of the patients with follicular lymphoma who had failed previous treatment responded to MabThera.
U ispitivanjima u kojima se lijek MabThera davao kao monoterapija (203 bolesnika), 48 % bolesnika s folikularnim limfomom koji nisu reagirali na prethodno liječenje reagirali su na lijek MabThera.
In a study (Study 03579) of 136 neutropenic paediatric patients 11 months – 17 years treated with posaconazole oral suspension at doses up to 18 mg/kg/day divided TID, approximately 50% met the prespecified target (Day 7 Cav between 500 ng/mL-2,500 ng/mL) (see section 5.2).
U ispitivanju (ispitivanje 03579) u kojem je sudjelovalo 136 pedijatrijskih bolesnika s neutropenijom u dobi od 11 mjeseci do 17 godina koji su liječeni posakonazol oralnom suspenzijom u dozama do najviše 18 mg/kg/dan podijeljeno u 3 doze, približno 50% njih dostiglo je unaprijed specificiranu ciljnu vrijednost (Cav u 7. danu liječenja između 500ng/ml – 2500 ng/ml) (vidjeti dio 5.2).
In a study comparing 8 patients with mild hepatic impairment (CPT Score A) to 8 matched controls and 8 patients with moderate hepatic impairment (CPT Score B) to 8 matched controls, the multiple dose exposure of rilpivirine was 47% higher in patients with mild hepatic impairment and 5% higher in patients with moderate hepatic impairment.
U ispitivanju u kojem se uspoređivalo 8 pacijenata s blagim oštećenjem jetre (CPT stadij A) s 8 odgovarajućih kontrolnih ispitanika te 8 pacijenata s umjerenim oštećenjem jetre (CPT stadij B) s 8 odgovarajućih kontrolnih ispitanika, izloženost nakon višestrukih doza rilpivirina bila je 47% veća u pacijenata s blagim oštećenjem jetre i 5% veća u pacijenata s umjerenim oštećenjem jetre.
In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment (Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment.
U ispitivanju u kojem je uspoređeno 8 ispitanika s blagim oštećenjem jetrene funkcije: Child-Pugh stadij A - 5 bodova (n = 6) i 6 bodova (n = 2) i 8 ispitanika s umjerenim oštećenjem jetrene funkcije: Child-Pugh stadij B - 7 bodova (n = 6) i 8 bodova (n = 2) sa 16 zdravih kontrolnih ispitanika, farmakokinetika i farmakodinamika jedne doze apiksabana od 5 mg nisu se promijenile u ispitanika s oštećenjem jetre.
In a study comparing 9 patients with mild (Child-Pugh A) hepatic impairment to 9 controls, the single and multiple dose exposure of tipranavir and ritonavir were increased in patients with hepatic impairment but still within the range observed in clinical studies.
U ispitivanju koje je uspoređivalo 9 bolesnika s blagim („Child-Pugh“ A) oštećenjem jetre s 9 kontrolnih ispitanika, izloženost tipranaviru s ritonavirom nakon jednokratne i višekratne primjene bila je veća u bolesnika s oštećenjem jetre, ali još uvijek unutar raspona primijećenog u kliničkim ispitivanjima.
In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (up to 4 mg per day) in patients with inadequate glycaemic control on metformin alone, treatment with empagliflozin daily resulted in superior reduction in HbA1c (Table 4), and a clinically meaningful reduction in FPG, compared to glimepiride.
U ispitivanju u kojem su uspoređivane djelotvornost i sigurnost empagliflozina 25 mg naspram glimepirida (do 4 mg na dan) u bolesnika s nezadovoljavajućom regulacijom glikemije na monoterapiji metforminom, svakodnevno liječenje empagliflozinom rezultiralo je superiornim sniženjem vrijednosti HbA1c (Tablica 4) te klinički značajnim sniženjem vrijednosti FPG u usporedbi s glimepiridom.
In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (up to 4 mg per day) in patients with inadequate glycaemic control on metformin alone, treatment with empagliflozin daily resulted in superior reduction in HbA1c (Table 5), and a clinically meaningful reduction in FPG, compared to glimepiride.
U ispitivanju u kojem su se usporedili djelotvornost i sigurnost empagliflozina od 25 mg naspram glimepirida (do 4 mg na dan) u bolesnika s nezadovoljavajućom regulacijom glikemije na monoterapiji metforminom svakodnevno liječenje empagliflozinom rezultiralo je superiornim sniženjem vrijednosti HbA1c (Tablica 5) te klinički značajnim sniženjem vrijednosti FPG u usporedbi s glimepiridom.
In a study comparing the efficacy and safety of the addition of linagliptin 5 mg or glimepiride (mean dose 3 mg) in patients with inadequate glycaemic control on metformin monotherapy, mean reductions in HbA1c were -0.16% with linagliptin (mean baseline HbA1c 7.69%) and -0.36% with glimepiride (mean baseline HbA1c 7.69%.) with a mean treatment difference of 0.20% (97.5% CI: 0.09, 0.299).
U ispitivanju koje je uspoređivalo djelotvornost i sigurnost dodavanja linagliptina 5 mg ili glimepirida (srednja doza od 3 mg) u bolesnika s nedostatnom kontrolom glikemije na monoterapiji metforminom, prosječna smanjenja HbA1c bila su -0,16% s linagliptinom (prosječna početna vrijednost HbA1c 7,69%) i -0,36% s glimeripidom (prosječna početna vrijednost HbA1c 7,69%) sa srednjom razlikom liječenja od 0,20% (97,5% CI: 0,09, 0,299).
In a study comparing the use of ribavirin dose reduction and erythropoesis stimulating agents in the management of treatment-emergent anaemia, the use of erythropoesis stimulating agents was associated with an increased risk of thromboembolic events (see section 5.1).
U ispitivanju u kojem se uspoređivalo sniženje doze ribavirina u odnosu na primjenu lijekova koji stimuliraju eritropoezu za liječenje anemije koja se javlja pri liječenju, primjena lijekova koji stimuliraju eritropoezu bila je povezana s povećanim rizikom od tromboembolijskih događaja (vidjeti dio 5.1).
In a study completed in 1996 recruiting less advanced HIV-1 infected patients (CD4 200-500 cells/l) without previous antiretroviral therapy, ritonavir in combination with zidovudine or alone reduced viral load in plasma and increased CD4 count.
U ispitivanju dovršenom 1996. godine, u bolesnika s manje uznapredovalom HIV-1 infekcijom (CD4: 200-500 stanica/l) bez prethodnog antiretrovirusnog liječenja, ritonavir u kombinaciji sa zidovudinom i ritonavir u monoterapiji, smanjio je broj virusnih čestica u plazmi i povećao broj CD4 stanica.
In a study completed in 1996 recruiting less advanced HIV-1 infected patients (CD4 200-500 cells/l) without previous antiretroviral therapy, ritonavir in combination with zidovudine or alone reduced viral load in plasma and increased CD4 count.
U ispitivanju dovršenom 1996. godine, u bolesnika s manje uznapredovalom HIV-1 infekcijom (CD4: 200-500 stanica/l) bez prethodnog antiretrovirusnog liječenja, ritonavir u kombinaciji sa zidovudinom i ritonavir u monoterapiji, smanjio je broj virusnih čestica u plazmi i povećao broj CD4stanica.
In a study conducted in beagle dog by intravenous bolus injection for 9 months, testicular findings (degeneration/necrosis of the seminiferous epithelium) have been observed.
U ispitivanju provedenom u pasa pasmine bigle, kojima su davane intravenske bolusne injekcije tijekom devet mjeseci, opažene su promjene na testisima (degeneracija/nekroza sjemenovodnog epitela).
In a study designed to assess the effect of heat on the transdermal delivery of granisetron from SANCUSO in healthy subjects, a heat pad generating an average temperature of 42°C was applied over the transdermal patch for 4 hours each day over the 5 day period of wear.
U ispitivanju provedenom radi procjenjivanja učinaka topline na transdermalnu primjenu granisetrona putem lijeka SANCUSO u zdravih ispitanika, na transdermalni flaster postavljen je grijaći jastuk koji je proizvodio prosječnu temperaturu od 42°C u trajanju 4 sata svakog dana tijekom 5 dana nošenja.
In a study evaluating conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant patients, increased urinary protein excretion was commonly observed at 6 to 24 months after conversion to Rapamune (see section 5.1).
U ispitivanju kojim se procjenjivao prelazak s inhibitora kalcineurina na Rapamune u bolesnika koji održavaju presadak bubrega, često je opaženo povećano izlučivanje proteina u urinu 6 do 24 mjeseci poslije prelaska na Rapamune (vidjeti dio 5.1).
In a study evaluating the safety and efficacy of conversion from calcineurin inhibitors to sirolimus (target levels of 12 - 20 ng/mL in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n=90) with a baseline glomerular filtration rate of less than 40 mL/min (see section 5.1).
U ispitivanju kojim se procjenjivala sigurnost i djelotvornost zamjene terapije inhibitorima kalcineurina sirolimusom (ciljane koncentracije 12 – 20 ng/ml) u bolesnika s održavanjem presatka bubrega, zaustavljeno je uključivanje bolesnika u podskupini (n=90) s početnom brzinom glomerularne filtracije manjom od 40 ml/min (vidjeti dio 5.1).
In a study evaluating the safety and efficacy of conversion from calcineurin inhibitors to sirolimus (target levels of 12-20 ng/mL in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n=90) with a baseline glomerular filtration rate of less than 40 mL/min (see section 5.1).
U ispitivanju kojim se procjenjivala sigurnost i djelotvornost zamjene terapije inhibitorima kalcineurina sirolimusom (ciljane koncentracije 12 – 20 ng/ml) u bolesnika s održavanjem presatka bubrega zaustavljeno je uključivanje bolesnika u podskupini (n=90) s početnom brzinom glomerularne filtracije manjom od 40 ml/min (vidjeti dio 5.1).
In a study in 118 children newly diagnosed with ALL, 75% of those treated with Oncaspar (in combination with other medicines) were free of the cancer after 7 years without having relapse or a new cancer.
U ispitivanju provedenom na 118 djece kojima je novodijagnosticirana bolest ALL, u 75 % bolesnika liječenih lijekom Oncaspar (u kombinaciji s drugim lijekovima) rak više nije bio prisutan nakon 7 godina, bez recidiva ili novog raka.
In a study in 158 children aged 6 to 16 years with symptomatic asthma, the combination of fluticasone propionate/salmeterol is as efficacious as doubling the dose of fluticasone propionate in respect of symptom control and lung function.
U ispitivanju u 158 djece u dobi od 6 do 16 godina sa simptomatskom astmom, kombinacija flutikazonpropionata/salmeterola jednako je učinkovita s obzirom na kontrolu simptoma i plućnu funkciju kao i udvostručenje doze flutikazonpropionata.
In a study in 545 randomised patients not adequately responsive to 5 mg amlodipine, the combination of aliskiren 150 mg/amlodipine 5 mg resulted in greater blood pressure reduction than those patients remaining on amlodipine 5 mg.
U ispitivanju 545 randomiziranih bolesnika s neodgovarajućim odgovorom na amlodipin 5 mg, primjena kombinacije aliskiren 150 mg/ amlodipin 5 mg rezultirala je većim sniženjem krvnog tlaka nego u onih bolesnika koji su ostali na amlodipinu 5 mg.
In a study in 69 children, Elocta was similarly effective: 2 bleeding episodes occurred per year on average and 81% of bleeding episodes resolved with only one injection.
U ispitivanju provedenom na 69 djece lijek Elocta pokazao je sličnu djelotvornost: u prosjeku su se javljala dva slučaja krvarenja u jednoj godini, a 81 % slučajeva krvarenja riješeno je samo jednom injekcijom.
In a study in breast- feeding, healthy women, olanzapine was excreted in breast milk.
U ispitivanju na zdravim dojiljama olanzapin se izlučivao u majčino mlijeko.
In a study in breast-feeding, healthy women, olanzapine was excreted in breast milk.
U ispitivanju na zdravim dojiljama olanzapin se izlučivao u majčino mlijeko.
In a study in breast.feeding, healthy women, olanzapine was excreted in breast milk.
U ispitivanju na zdravim dojiljama, olanzapin se izlučivao u majčino mlijeko.
In a study in elderly men and women including 4 patients >75 years of age, AUC was about 30 and 50% increased compared to young men, respectively.
U ispitivanju sa starijim muškarcima i ženama, uključujući 4 bolesnika starija od 75 godina života, AUC je bio veći za oko 30, odnosno 50% nego kod mladih muškaraca.
In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo.
Tijekom ispitivanja na zdravim ispitanicima, istodobna primjena 120 mg febuksostata jednom dnevno s jednokratnom oralnom dozom od 4 mg roziglitazona nije imala učinak na farmakokinetiku roziglitazona i njegova metabolita N- dezmetilroziglitazona, što pokazuje da febuksostat nije inhibitor enzima CYP2C8 in vivo.